# Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

> **NCT04193098** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Second-line Treatment

## Interventions

- **BIOLOGICAL:** CTL
- **BIOLOGICAL:** Toripalimab

## Key facts

- **NCT ID:** NCT04193098
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04193098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04193098, "Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04193098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*